Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides
- PMID:18765824
- DOI: 10.1158/1535-7163.MCT-08-0427
Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides
Abstract
We have studied the potential contribution of ABCG2 (breast cancer resistance protein) to resistance to nucleoside analogues. In cells transfected with DNA constructs resulting in overexpression of human or mouse ABCG2, we found resistance against cladribine, clofarabine, fludarabine, 6-mercaptopurine, and 6-mercaptopurine riboside in both MDCKII and HEK293 cells and against gemcitabine only in HEK293 cells. With Transwell studies in MDCK cells and transport experiments with vesicles from Sf9 and HEK293 cells, we show that ABCG2 is able to transport not only the nucleotide CdAMP, like several other ATP-binding cassette transporters of the ABCC (multidrug resistance protein) family, but also the nucleoside cladribine itself. Expression of ABCG2 in cells results in a substantial decrease of intracellular CdATP, explaining the resistance against cladribine. The high transport rate of cladribine and clofarabine by ABCG2 deduced from Transwell experiments raises the possibility that this transporter could affect the disposition of nucleoside analogues in patients or cause resistance in tumors.
Similar articles
- Deoxycytidine kinase modulates the impact of the ABC transporter ABCG2 on clofarabine cytotoxicity.Nagai S, Takenaka K, Nachagari D, Rose C, Domoney K, Sun D, Sparreboom A, Schuetz JD.Nagai S, et al.Cancer Res. 2011 Mar 1;71(5):1781-91. doi: 10.1158/0008-5472.CAN-10-1919. Epub 2011 Jan 18.Cancer Res. 2011.PMID:21245102Free PMC article.
- ABC transporters and their role in nucleoside and nucleotide drug resistance.Fukuda Y, Schuetz JD.Fukuda Y, et al.Biochem Pharmacol. 2012 Apr 15;83(8):1073-83. doi: 10.1016/j.bcp.2011.12.042. Epub 2012 Jan 20.Biochem Pharmacol. 2012.PMID:22285911Free PMC article.Review.
- The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M, Dean M, Sharp JG, Cowan K.Kim M, et al.Clin Cancer Res. 2002 Jan;8(1):22-8.Clin Cancer Res. 2002.PMID:11801536
- Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR Jr, Huang Y, Robey RW, Liang YJ, Chen LM, Shi CJ, Ambudkar SV, Chen ZS, Fu LW.Dai CL, et al.Cancer Res. 2008 Oct 1;68(19):7905-14. doi: 10.1158/0008-5472.CAN-08-0499.Cancer Res. 2008.PMID:18829547Free PMC article.
- Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).Doyle L, Ross DD.Doyle L, et al.Oncogene. 2003 Oct 20;22(47):7340-58. doi: 10.1038/sj.onc.1206938.Oncogene. 2003.PMID:14576842Review.
Cited by
- The role of transporters in the toxicity of nucleoside and nucleotide analogs.Koczor CA, Torres RA, Lewis W.Koczor CA, et al.Expert Opin Drug Metab Toxicol. 2012 Jun;8(6):665-76. doi: 10.1517/17425255.2012.680885. Epub 2012 Apr 18.Expert Opin Drug Metab Toxicol. 2012.PMID:22509856Free PMC article.Review.
- Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy.Lister A, Nedjadi T, Kitteringham NR, Campbell F, Costello E, Lloyd B, Copple IM, Williams S, Owen A, Neoptolemos JP, Goldring CE, Park BK.Lister A, et al.Mol Cancer. 2011 Apr 13;10:37. doi: 10.1186/1476-4598-10-37.Mol Cancer. 2011.PMID:21489257Free PMC article.
- Engineered matrices reveal stiffness-mediated chemoresistance in patient-derived pancreatic cancer organoids.LeSavage BL, Zhang D, Huerta-López C, Gilchrist AE, Krajina BA, Karlsson K, Smith AR, Karagyozova K, Klett KC, Huang MS, Long C, Kaber G, Madl CM, Bollyky PL, Curtis C, Kuo CJ, Heilshorn SC.LeSavage BL, et al.Nat Mater. 2024 Aug;23(8):1138-1149. doi: 10.1038/s41563-024-01908-x. Epub 2024 Jul 4.Nat Mater. 2024.PMID:38965405
- Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases.Robak T, Korycka A, Lech-Maranda E, Robak P.Robak T, et al.Molecules. 2009 Mar 23;14(3):1183-226. doi: 10.3390/molecules14031183.Molecules. 2009.PMID:19325518Free PMC article.Review.
- Human ABCG2: structure, function, and its role in multidrug resistance.Mo W, Zhang JT.Mo W, et al.Int J Biochem Mol Biol. 2012;3(1):1-27. Epub 2011 Mar 30.Int J Biochem Mol Biol. 2012.PMID:22509477Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical